Predictive Oncology Inc. has expanded the applications of its AI platform to account for patient heterogeneity and increase the Probability of Technical Success in drug discovery. The platform utilizes AI and machine learning to introduce patient heterogeneity in the early stages of drug discovery, reducing the risk of failure in later clinical trials.